UiPath (NYSE:PATH) PT Lowered to $17.00 at JPMorgan Chase & Co.

UiPath (NYSE:PATH) had its price objective dropped by equities research analysts at JPMorgan Chase & Co. from $19.00 to $17.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 42.50% from the company’s previous close.

PATH has been the topic of several other reports. Morgan Stanley reissued an “equal weight” rating and set a $15.00 price objective on shares of UiPath in a research note on Friday, September 6th. Bank of America boosted their price objective on UiPath from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Evercore ISI upped their target price on UiPath from $13.00 to $16.00 and gave the company an “in-line” rating in a research note on Friday, September 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Wednesday. Finally, Wells Fargo & Company lowered their target price on UiPath from $15.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday. Sixteen analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $17.47.

UiPath Trading Down 5.6 %

NYSE PATH traded down $0.71 on Wednesday, hitting $11.93. 8,243,720 shares of the company traded hands, compared to its average volume of 9,719,182. The company has a market capitalization of $6.56 billion, a price-to-earnings ratio of -59.85 and a beta of 0.88. The business’s 50 day moving average price is $12.46 and its 200-day moving average price is $14.24. UiPath has a 52-week low of $10.37 and a 52-week high of $27.87.

UiPath (NYSE:PATH) last released its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. The company had revenue of $316.00 million for the quarter, compared to the consensus estimate of $303.69 million. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. UiPath’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.09) earnings per share. As a group, sell-side analysts predict that UiPath will post -0.23 earnings per share for the current year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the transaction, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at $10,258,498.19. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.37% of the stock is owned by insiders.

Institutional Trading of UiPath

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of UiPath by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock valued at $911,741,000 after buying an additional 2,133,078 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in UiPath by 0.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 295,370 shares of the healthcare company’s stock valued at $6,696,000 after purchasing an additional 1,571 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in UiPath by 3,389.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 89,189 shares of the healthcare company’s stock valued at $1,131,000 after purchasing an additional 86,633 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its holdings in UiPath by 4.2% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 231,694 shares of the healthcare company’s stock valued at $5,240,000 after purchasing an additional 9,393 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in UiPath by 245.1% in the 1st quarter. Acadian Asset Management LLC now owns 45,700 shares of the healthcare company’s stock valued at $1,032,000 after purchasing an additional 32,456 shares during the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.